Video

Kate Dawson from Biogen: New Research Shows Long Term Benefits of Tecfidera

Author(s):

As more research is collected about Tecfidera's usage since clinical trials and approval there continue to be signs that it can be a good treatment option for patients with multiple sclerosis, especially in the earliest stages.

As more research is collected about Tecfidera's usage since clinical trials and approval there continue to be signs that it can be a good treatment option for patients with multiple sclerosis, especially in the earliest stages.

At the 68th Annual Meeting of the American Academy of Neurology Kate Dawson, MD, from Biogen discussed some of the latest results from one of the newest approved treatments for the condition. While being relatively new Dawson said the results show the medication to be a viable option which can help this patient population.

Related Videos
Understanding Angioedema in Urticaria, with Jonathan Bernstein, MD
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
© 2025 MJH Life Sciences

All rights reserved.